Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer
- 19 August 2016
- journal article
- research article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 239, 39-48
- https://doi.org/10.1016/j.jconrel.2016.08.016
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Biocompatible nanocomposite for PET/MRI hybrid imagingInternational Journal of Nanomedicine, 2012
- Genetically Engineered Mouse Models of Pancreatic CancerThe Cancer Journal, 2012
- Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancerTherapeutic Advances in Medical Oncology, 2012
- Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesisOncogene, 2012
- Nanoparticle PEGylation for Imaging and TherapyNanomedicine, 2011
- Single Chain Epidermal Growth Factor Receptor Antibody Conjugated Nanoparticles for in vivo Tumor Targeting and ImagingSmall, 2009
- Kupffer cells are central in the removal of nanoparticles from the organismParticle and Fibre Toxicology, 2007
- Targeted pharmaceutical nanocarriers for cancer therapy and imagingThe AAPS Journal, 2007
- Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug deliveryBiomaterials, 2007
- Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapyNature Reviews Cancer, 2006